Journey MedicalDERM -0.96%62 Return-on-Tangible-Asset is -13.51% as of Mar. 2026. GuruFocus rates DERM with a GF Score™ of 62/100 and a GF Value™ of $4.20 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 1,005 Drug Manufacturers companies, Journey Medical ranks worse than 81.59% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Journey Medical's annualizedNet Income for the quarter that ended in Mar. 2026 was $-8.92 Mil. Journey Medical's average total tangible assets for the quarter that ended in Mar. 2026 was $66.02 Mil. Therefore, Journey Medical's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2026 was -13.51%.
The historical rank and industry rank for Journey Medical's Return-on-Tangible-Asset or its related term are showing as below:
DERM'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -72.35 Med: -19.82 Max: 16.68
Current: -16.3
During the past 7 years, Journey Medical's highest Return-on-Tangible-Asset was 16.68%. The lowest was -72.35%. And the median was -19.82%.
DERM's Return-on-Tangible-Asset is ranked worse than 81.59% of 1005
companies
in the Drug Manufacturers industry
Industry Median: 3.16
vs DERM: -16.30
Journey Medical (NAS:DERM) Return-on-Tangible-Asset Explanation
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Journey Medical Return-on-Tangible-Asset Related Terms
Journey Medical Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Journey Medical's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DERM vs LFCR, ANIK, ASRT: Return-on-Tangible-Asset Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Journey Medical's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Journey Medical Return-on-Tangible-Asset vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Journey Medical's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Journey Medical's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
What does a Return-on-Tangible-Asset of -13.51% mean?
Journey Medical (DERM) has a Return-on-Tangible-Asset of -13.51% as of Mar. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Journey Medical and its competitors. According to the industry distribution chart, Journey Medical ranks #820 out of 1005 companies in the Drug Manufacturers industry, placing it in the top 81.6%.
Is Journey Medical's Return-on-Tangible-Asset too high?
Journey Medical's current Return-on-Tangible-Asset is -13.51%. Based on the distribution chart, Journey Medical ranks #820 out of 1005 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Journey Medical has a GF Score™ of 62/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Journey Medical's Return-on-Tangible-Asset compare to LFCR and ANIK?
According to the Drug Manufacturers industry distribution chart, Journey Medical ranks #820 out of 1005 companies for Return-on-Tangible-Asset. This places Journey Medical in the lower half of its industry. The industry median Return-on-Tangible-Asset is 3.16. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Drug Manufacturers company?
The median Return-on-Tangible-Asset among Drug Manufacturers companies is 3.16, based on 1,005 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Journey Medical and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Asset is 3.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Journey Medical's current Return-on-Tangible-Asset is -13.51%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Journey Medical stock overvalued right now?
Based on GuruFocus' analysis, Journey Medical (DERM) is currently considered Significantly Overvalued. The stock's GF Value™ is $4.20, compared to a current price of $6.66 — trading 58.7% above its estimated fair value. The current Return-on-Tangible-Asset is -13.51%. Journey Medical's overall GF Score™ is 62/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Journey Medical (DERM), the current Return-on-Tangible-Asset is -13.51% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Journey Medical (DERM) Overvalued in 2026?
Based on GuruFocus' analysis, Journey Medical stock appears to be overvalued.
The current stock price of $6.66 is trading 58.7% above its estimated GF Value™ of $4.20.
GuruFocus considers Journey Medical to be Significantly Overvalued.
Key valuation signals for DERM:
Return-on-Tangible-Asset: -13.51%
GF Value™: $4.20 vs. price of $6.66 (58.7% above fair value)
No single metric tells the full story. See the DERM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Journey Medical Corp is a commercial-stage pharmaceutical company that focuses on the selling and marketing of U.S. Food and Drug Administration (FDA) approved prescription pharmaceutical products for the treatment of dermatological conditions. Its current product portfolio includes FDA-approved prescription drugs for dermatological conditions that are marketed in the U.S. The company views its operations and manages its business in one segment, which reflects products for the treatment of dermatological conditions. The dermatological segment derives revenues from the sale of branded and authorized general prescription products that treat certain dermatological conditions.
62GF Score
Get the complete analysis for DERM
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DERM has been successfully added to your 
